Startup Labrys raises Series A funds and buys Pfizer's CGRP inhibitor
This article was originally published in Scrip
Executive Summary
San Francisco-based startup Labrys Biologics simultaneously closed the first $14.6 million of a $31 million Series A venture funding round and acquired the Phase II-ready RN-307 from Pfizer, becoming one of at least three private companies with calcitonin gene-related peptide (CGRP) inhibitors in development for prophylactic treatment of chronic migraine headaches.